Ocular Therapeutix, Inc.
OCUL
$9.16
-$0.12-1.29%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 52.04M | 51.95M | 55.78M | 56.66M | 59.65M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 52.04M | 51.95M | 55.78M | 56.66M | 59.65M |
| Cost of Revenue | 227.09M | 203.67M | 193.50M | 177.98M | 155.32M |
| Gross Profit | -175.06M | -151.72M | -137.71M | -121.31M | -95.67M |
| SG&A Expenses | 124.38M | 118.30M | 113.72M | 107.42M | 100.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 351.48M | 321.97M | 307.22M | 285.40M | 255.63M |
| Operating Income | -299.44M | -270.02M | -251.43M | -228.73M | -195.98M |
| Income Before Tax | -290.50M | -265.94M | -249.67M | -216.75M | -192.71M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -290.50 | -265.94 | -249.67 | -216.75 | -192.71 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -290.50M | -265.94M | -249.67M | -216.75M | -192.71M |
| EBIT | -299.44M | -270.02M | -251.43M | -228.73M | -195.98M |
| EBITDA | -294.81M | -265.69M | -247.41M | -224.82M | -192.13M |
| EPS Basic | -1.46 | -1.44 | -1.44 | -1.28 | -1.15 |
| Normalized Basic EPS | -0.91 | -0.90 | -0.90 | -0.80 | -0.69 |
| EPS Diluted | -1.46 | -1.44 | -1.44 | -1.28 | -1.15 |
| Normalized Diluted EPS | -0.91 | -0.90 | -0.90 | -0.80 | -0.69 |
| Average Basic Shares Outstanding | 803.54M | 748.83M | 693.93M | 677.00M | 670.23M |
| Average Diluted Shares Outstanding | 803.54M | 748.83M | 693.93M | 677.00M | 670.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |